美股异动丨诺和诺德大跌近16%，礼来涨超4%

Core Viewpoint - Novo Nordisk (NVO.US) experienced a significant drop of nearly 16%, trading at $39.97, while Eli Lilly (LLY.US) saw an increase of over 4%, trading at $1055.47. This market reaction follows Novo Nordisk's announcement that its weight loss drug Cagrisema showed less effective results compared to Eli Lilly's Zepbound [1]. Company Summary - Novo Nordisk's Cagrisema drug trial results were disappointing, leading to a sharp decline in its stock price [1]. - Eli Lilly's Zepbound demonstrated superior efficacy in comparison to Cagrisema, contributing to Eli Lilly's stock price increase [1].